Cite
Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence
MLA
Jeffrey A. Barnes, et al. “Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence.” Blood, vol. 138, Nov. 2021, p. 3753. EBSCOhost, https://doi.org/10.1182/blood-2021-150961.
APA
Jeffrey A. Barnes, Jenny Wu, Anita A Kumar, Krista J Scorsune, Allison P. Jacob, Jade Ruiters, Connie Lee Batlevi, Rosalba Martignetti, Chaya Friedman, Venkatraman E. Seshan, Daneal Portman, Audrey Hamilton, Ai Ni, Anthony R. Mato, Morgan Choma, Meghan C. Thompson, Clare Grieve, Jane Huang, Elizabeth Simkins, … Jeremy S. Abramson. (2021). Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence. Blood, 138, 3753. https://doi.org/10.1182/blood-2021-150961
Chicago
Jeffrey A. Barnes, Jenny Wu, Anita A Kumar, Krista J Scorsune, Allison P. Jacob, Jade Ruiters, Connie Lee Batlevi, et al. 2021. “Zanubrutinib, Obinutuzumab, and Venetoclax in Chronic Lymphocytic Leukemia: Early MRD Kinetics Define a High-Risk Patient Cohort with Delayed Bone Marrow Undetectable MRD and Earlier Post-Treatment MRD Recurrence.” Blood 138 (November): 3753. doi:10.1182/blood-2021-150961.